Published in Int J Cancer on November 01, 2010
Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer (2012) 2.52
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab (2010) 1.34
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One (2011) 1.32
Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29
O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta (2012) 1.22
Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer (2014) 1.05
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med (2012) 1.03
Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res (2013) 1.03
Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One (2011) 1.01
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis (2013) 0.98
MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget (2014) 0.98
The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. Transl Oncol (2012) 0.88
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res (2014) 0.87
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther (2014) 0.83
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. Medicine (Baltimore) (2015) 0.80
A comprehensive profile of recurrent glioblastoma. Oncogene (2016) 0.79
Expression of O(6)-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal Tissue. J Cancer Ther (2013) 0.79
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs (2013) 0.79
O(6)-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma. BBA Clin (2015) 0.77
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. Mol Pharm (2015) 0.76
MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Clin Epigenetics (2016) 0.76
Overexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expression. Int J Clin Exp Pathol (2015) 0.75
Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Oncotarget (2017) 0.75
Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma. J Res Med Sci (2014) 0.75
Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci (2005) 28.08
Multimodal fast optical interrogation of neural circuitry. Nature (2007) 14.68
Light-induced activation of distinct modulatory neurons triggers appetitive or aversive learning in Drosophila larvae. Curr Biol (2006) 6.40
Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med (2009) 4.87
DNA damage-induced cell death by apoptosis. Trends Mol Med (2006) 4.67
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest (2005) 3.22
Spectral characteristics of the photocycle of channelrhodopsin-2 and its implication for channel function. J Mol Biol (2007) 2.88
DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett (2012) 2.69
Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke (2007) 2.54
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol (2003) 2.38
Mechanisms of human DNA repair: an update. Toxicology (2003) 2.24
Fast manipulation of cellular cAMP level by light in vivo. Nat Methods (2006) 2.15
Structural guidance of the photocycle of channelrhodopsin-2 by an interhelical hydrogen bond. Biochemistry (2010) 2.11
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem (2006) 2.08
From traditional Chinese medicine to rational cancer therapy. Trends Mol Med (2007) 2.02
Spatially asymmetric reorganization of inhibition establishes a motion-sensitive circuit. Nature (2010) 2.01
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
Light modulation of cellular cAMP by a small bacterial photoactivated adenylyl cyclase, bPAC, of the soil bacterium Beggiatoa. J Biol Chem (2010) 1.94
Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta (2010) 1.93
Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle (2010) 1.88
Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets (2006) 1.77
Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis (2003) 1.54
Propofol impairs neurogenesis and neurologic recovery and increases mortality rate in adult rats after traumatic brain injury. Crit Care Med (2014) 1.52
Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol (2013) 1.50
Severe forward flexion of the trunk in Parkinson's disease: focal myopathy of the paraspinal muscles mimicking camptocormia. Mov Disord (2003) 1.49
DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A (2010) 1.48
How DNA lesions are turned into powerful killing structures: insights from UV-induced apoptosis. Mutat Res (2008) 1.43
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol (2006) 1.43
Toxicity of the antimalarial artemisinin and its dervatives. Crit Rev Toxicol (2010) 1.41
A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab (2007) 1.39
Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med (2004) 1.37
Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res (2008) 1.31
"Vision" in single-celled algae. News Physiol Sci (2004) 1.30
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol (2009) 1.30
Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) (2008) 1.29
Conformational changes of channelrhodopsin-2. J Am Chem Soc (2009) 1.28
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One (2013) 1.24
Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther (2008) 1.22
Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer (2010) 1.22
Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res (2007) 1.21
From channelrhodopsins to optogenetics. EMBO Mol Med (2013) 1.21
Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol (2005) 1.17
O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta (2011) 1.16
Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer (2004) 1.16
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys (2009) 1.16
APE/Ref-1 and the mammalian response to genotoxic stress. Toxicology (2003) 1.15
Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress. Proc Natl Acad Sci U S A (2011) 1.14
Phosphorylation of mismatch repair proteins MSH2 and MSH6 affecting MutSalpha mismatch-binding activity. Nucleic Acids Res (2002) 1.14
Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol (2010) 1.12
Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J (2003) 1.11
The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis (2010) 1.11
Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther (2011) 1.10
Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene (2002) 1.09
Molecular biology of cantharidin in cancer cells. Chin Med (2007) 1.08
MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer (2008) 1.08
Oxygen therapy reduces secondary hemorrhage after thrombolysis in thromboembolic cerebral ischemia. J Cereb Blood Flow Metab (2010) 1.07
Effects of neural progenitor cells on sensorimotor recovery and endogenous repair mechanisms after photothrombotic stroke. Stroke (2011) 1.07
FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS One (2011) 1.07
Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res (2007) 1.07
Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models. Brain Pathol (2012) 1.06
Toxicities by herbal medicines with emphasis to traditional Chinese medicine. Curr Drug Metab (2011) 1.05
Optogenetic long-term manipulation of behavior and animal development. PLoS One (2011) 1.05
Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol (2011) 1.05
Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol (2007) 1.04
PACα--an optogenetic tool for in vivo manipulation of cellular cAMP levels, neurotransmitter release, and behavior in Caenorhabditis elegans. J Neurochem (2011) 1.04
Cell proliferation and DNA breaks are involved in ultraviolet light-induced apoptosis in nucleotide excision repair-deficient Chinese hamster cells. Mol Biol Cell (2002) 1.03
The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice. J Neurosci (2009) 1.03
Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neurosci Lett (2006) 1.03
Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res (2013) 1.03
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta (2012) 1.02
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res (2010) 1.02
Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate. DNA Repair (Amst) (2010) 1.01
Influence of DNA repair on nonlinear dose-responses for mutation. Toxicol Sci (2013) 1.01
Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One (2011) 1.01
Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. Mutat Res (2009) 1.01
Neuroprotection by hyperbaric oxygenation after experimental focal cerebral ischemia monitored by MRI. Stroke (2004) 1.01
Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res (2007) 1.01
Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol Appl Pharmacol (2008) 1.00
Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med (2013) 0.99
Dose-related efficacy of a continuous intracisternal nimodipine treatment on cerebral vasospasm in the rat double subarachnoid hemorrhage model. Neurosurgery (2009) 0.99
Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene (2004) 0.98
FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res (2009) 0.98
Immunohistochemical analysis of KCNQ2 potassium channels in adult and developing mouse brain. Brain Res (2006) 0.98
Fen1 is induced p53 dependently and involved in the recovery from UV-light-induced replication inhibition. Oncogene (2005) 0.98
Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett (2003) 0.98
Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett (2003) 0.97
Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke. Exp Neurol (2004) 0.97
Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons. J Biol Chem (2012) 0.96
Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res (2008) 0.96
Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res (2006) 0.96
Predicting the "usefulness" of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European survey. Acta Neurochir (Wien) (2014) 0.96
Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett (2005) 0.95
Different affinities of inhibitors to the outwardly and inwardly directed substrate binding site of organic cation transporter 2. Mol Pharmacol (2003) 0.94
Delayed manifestation of spinal metastasis: a special feature of hemangiopericytoma. Clin Neurol Neurosurg (2003) 0.94
Visualizing cell death in experimental focal cerebral ischemia: promises, problems, and perspectives. J Cereb Blood Flow Metab (2011) 0.94
A role for UV-light-induced c-Fos: Stimulation of nucleotide excision repair and protection against sustained JNK activation and apoptosis. Carcinogenesis (2006) 0.93
Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res (2005) 0.93